DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis

Information source: Hoffmann-La Roche
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Post Menopausal Osteoporosis

Intervention: ibandronate [Bonviva/Boniva] (Drug); ibandronate [Bonviva/Boniva] (Drug); ibandronate [Bonviva/Boniva] (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Hoffmann-La Roche

Official(s) and/or principal investigator(s):
Clinical Trials, Study Director, Affiliation: Hoffmann-La Roche


This study will assess the efficacy and safety of intravenous administration of Bonviva regimens in women with post-menopausal osteoporosis, compared to oral daily administration. Patients will also receive daily supplementation with vitamin D and calcium. The anticipated time of study treatment is 2+ years, and the target sample size is 500+ individuals.

Clinical Details

Official title: A Randomized, Double-blind Study Comparing the Effect of Different Treatment Regimens of Intravenous Bonviva on Lumbar Bone Mineral Density in Women With Osteoporosis

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Relative change (%) from baseline in mean lumbar spine bone mineral density (BMD) \n\n

Secondary outcome:

Relative change in mean lumbar spine BMD\n

Relative and absolute change in total hip, trochanter, femoral neck BMD

Percentage of responders

Change from baseline in fastin serum CTX

AEs, laboratory parameters


Minimum age: 55 Years. Maximum age: 80 Years. Gender(s): Female.


Inclusion Criteria:

- women 55-80 years of age;

- post-menopausal for >=5 years;

- ambulatory.

Exclusion Criteria:

- malignant disease diagnosed within the previous 10 years (except basal cell cancer

that has been successfully removed);

- breast cancer within the previous 20 years;

- allergy to bisphosphonates;

- previous treatment with an intravenous bisphosphonate at any time;

- previous treatment with an oral bisphosphonate within the last 6 months, >1 month of

treatment within the last year, or >3 months of treatment within the last 2 years.

Locations and Contacts

Darlinghurst 2010, Australia

Melbourne 3084, Australia

Nedlands 6000, Australia

St. Leonards 2139, Australia

Sydney 3129, Australia

Bruxelles 1180, Belgium

Liege 4020, Belgium

Plzen 305 99, Czech Republic

Praha 128 00, Czech Republic

Aalborg 9000, Denmark

Ballerup 2750, Denmark

København 1399, Denmark

Vejle 7100, Denmark

Århus 8000, Denmark

Lyon 69437, France

Orleans 45000, France

Berlin 12200, Germany

Bochum 44789, Germany

Hamburg 20246, Germany

Budapest 1036, Hungary

Arenzano 16011, Italy

Siena 53100, Italy

Valeggio Sul Mincio 37067, Italy

Mexico City 11000, Mexico

Monterrey 64460, Mexico

Haugesund 5507, Norway

Oslo 0176, Norway

Stavanger 4010, Norway

Grudziadz 86-300, Poland

Krakow 30-510, Poland

Krakow 31-501, Poland

Cape Town 7500, South Africa

Pretoria, South Africa

Sommerset West 7129, South Africa

Barcelona 08003, Spain

Madrid 28046, Spain

Santander 39008, Spain

Aberdeen AB25 1LD, United Kingdom

Manchester M13 9WL, United Kingdom

Newcastle Upon Tyne NE7 7DN, United Kingdom

Little Rock, Arkansas 72205-7199, United States

Irvine, California 92618, United States

Rancho Mirage, California 92270, United States

Leesburg, Florida 34748, United States

Gainesville, Georgia 30501, United States

Coeur D'alene, Idaho 83814, United States

Bethesda, Maryland 20817, United States

St Louis, Missouri 63110, United States

Billings, Montana 59120, United States

Omaha, Nebraska 68131, United States

Albuquerque, New Mexico 87106, United States

New York, New York 10029, United States

Bismarck, North Dakota 58503, United States

Fargo, North Dakota 58103, United States

Toronto, Ontario M5C 2T2, Canada

Wyomissing, Pennsylvania 19610, United States

Laval, Quebec H7T 2P5, Canada

Montreal, Quebec H2X 3J4, Canada

Montreal, Quebec H3A 1A1, Canada

Saskatoon, Saskatchewan S7K 0H6, Canada

Rapid City, South Dakota 57701, United States

San Antonio, Texas 78229, United States

Virginia Beach, Virginia 23462, United States

Madison, Wisconsin 53792, United States

Additional Information

Starting date: May 2002
Last updated: August 17, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017